A comparison of two supplemental procedures for confirmation of antibody to hepatitis C virus c100-3 antigen in Louisiana blood donors.
In a pilot study designed to evaluate the performance of supplemental hepatitis C virus (HCV) tests, 146 consecutive HCV enzyme immunoassay (EIA)-reactive samples (0.98% of 14,949 donors) were comparatively evaluated with two sets of supplemental tests: HCV antibody neutralization/c100-3 peptide EIA and the first-generation HCV recombinant immunoblot assay (RIBA). Of these samples, 68.5 percent were positive and 17.8 percent were negative on both supplemental assays. Nineteen samples were discordant. Eleven samples were positive on one assay (9 on neutralization/peptide, 2 on RIBA) and negative or indeterminate on the alternate supplemental test, but reacted with two additional HCV antigens outside the c100-3 region in a second-generation dot immunoblot assay. The dot immunoblot assay was used as a reference and reactive samples were considered confirmed. The remaining eight discordant samples were indeterminate or negative on either assay and did not react on the dot immunoblot assay. These data indicate a 0.74-percent prevalence of HCV exposure detected by reactivity with the c100-3 antigen in blood donors in southern Louisiana.
Smith
D
D
Blood Center for Southeast Louisiana, New Orleans.
Delaney
S
S
Allain
J P
JP
Vallari
D
D
Lee
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000956:Antigens, Viral; D001782:Blood Donors / Q000706:statistics & numerical data; D005260:Female; D006508:Hepatitis Antibodies / Q000097:blood*; D006526:Hepatitis C / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques; D008145:Louisiana / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D015995:Prevalence; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins / Q000276:immunology*
D000956:Antigens, Viral; C064544:C100 protein, hepatitis C virus; D006508:Hepatitis Antibodies; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins